| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Eva Feldman | Q5415042 |
| Lucy M Hinder | Q57023938 | ||
| Rodica Pop-Busui | Q58677380 | ||
| P2093 | author name string | Andrea M Vincent | |
| P2860 | cites work | Receptor for Advanced Glycation End Products Activation Injures Primary Sensory Neurons via Oxidative Stress | Q56610055 |
| The metabolic syndrome and cardiovascular disease | Q58271154 | ||
| Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. | Q64907197 | ||
| Induction of apoptosis and secondary necrosis in rat dorsal root ganglion cell cultures by oxidized low density lipoprotein | Q71334276 | ||
| Neuropathy associated with hyperlipidemia | Q72829602 | ||
| Oxidized high-density lipoprotein induces neuron death | Q73472019 | ||
| The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM) | Q73676318 | ||
| Oxidized lipoproteins activate NF-kappaB binding activity and apoptosis in PC12 cells | Q74344677 | ||
| Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort | Q77764997 | ||
| Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol | Q80012062 | ||
| Reducing ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits | Q80229473 | ||
| Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway | Q80838580 | ||
| The metabolic syndrome: progress towards one definition for an epidemic of our time | Q81127296 | ||
| Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver | Q83951414 | ||
| Fenofibrate and diabetic retinopathy | Q94691490 | ||
| Metformin monotherapy for type 2 diabetes mellitus | Q24246552 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids--update on the background of the current guidelines | Q28171307 | ||
| Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease | Q28260195 | ||
| The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin | Q28296378 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| Fenofibrate for diabetic retinopathy | Q33305305 | ||
| Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. | Q33305306 | ||
| Diabetic neuropathy: mechanisms to management | Q33554384 | ||
| Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy | Q33709276 | ||
| Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation | Q34546113 | ||
| Mechanisms of disease: the oxidative stress theory of diabetic neuropathy | Q34553052 | ||
| Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. | Q34576734 | ||
| Lipoprotein receptors in the nervous system | Q34667437 | ||
| Oxidized lipoproteins may play a role in neuronal cell death in Alzheimer disease | Q34747005 | ||
| Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models | Q35184850 | ||
| Lipoprotein abnormalities and their consequences for patients with type 2 diabetes | Q35675497 | ||
| Oxidation of LDL, atherogenesis, and apoptosis | Q35700432 | ||
| New insights into the mechanisms of diabetic neuropathy. | Q35813649 | ||
| Oxidative stress in the pathogenesis of diabetic neuropathy | Q35856228 | ||
| The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? | Q36161631 | ||
| Vascular complications in diabetes mellitus: the role of endothelial dysfunction | Q36201628 | ||
| Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. | Q36203941 | ||
| New developments in diabetic neuropathy. | Q36254810 | ||
| SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy | Q36360471 | ||
| Idiopathic neuropathy, prediabetes and the metabolic syndrome | Q36382819 | ||
| A constellation of complications: the metabolic syndrome | Q36394357 | ||
| The metabolic syndrome, hyperlipidemia, and insulin resistance | Q36394371 | ||
| NADPH oxidase and heart failure | Q36398995 | ||
| Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes | Q36454830 | ||
| Oxidative stress and diabetes-associated complications | Q36454852 | ||
| Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. | Q36755721 | ||
| Advances in the management of painful diabetic neuropathy | Q36816573 | ||
| Oxidative stress and endothelial dysfunction in vascular disease | Q36905196 | ||
| Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review | Q36917017 | ||
| PPARs and diabetes-associated atherosclerosis | Q36952321 | ||
| The expression and down stream effect of lectin like-oxidized low density lipoprotein 1 (LOX-1) in hyperglycemic state | Q36972539 | ||
| Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice | Q36972748 | ||
| Glucose neurotoxicity | Q37038404 | ||
| Glucose metabolism and hyperglycemia | Q37050752 | ||
| Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion | Q37054976 | ||
| Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component | Q37065622 | ||
| The antioxidant response as a drug target in diabetic neuropathy | Q37065975 | ||
| Elevated triglycerides correlate with progression of diabetic neuropathy | Q37236277 | ||
| Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. | Q37360464 | ||
| Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). | Q37375125 | ||
| Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins | Q38295835 | ||
| Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium | Q38353224 | ||
| The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy | Q39452399 | ||
| Free radical modification of low-density lipoprotein: mechanisms and biological consequences | Q39511289 | ||
| LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes | Q40005574 | ||
| Phosphatidylinositol 3-kinase-dependent membrane recruitment of Rac-1 and p47phox is critical for alpha-platelet-derived growth factor receptor-induced production of reactive oxygen species | Q40037121 | ||
| Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations | Q40055172 | ||
| Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard | Q40241540 | ||
| Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages | Q40849035 | ||
| Opposing actions of native and oxidized lipoprotein on motor neuron-like cells. | Q40957744 | ||
| Pathogenesis of diabetic neuropathy. | Q41634272 | ||
| Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis | Q42484227 | ||
| The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia | Q43687892 | ||
| The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes | Q43763521 | ||
| Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort | Q44267502 | ||
| LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats | Q44380011 | ||
| Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. | Q44516272 | ||
| Oxidized LDL through LOX-1 modulates LDL-receptor expression in human coronary artery endothelial cells | Q44523793 | ||
| Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats | Q44530566 | ||
| Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death | Q44779270 | ||
| Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes | Q44795860 | ||
| A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population | Q44908082 | ||
| Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy | Q45034117 | ||
| Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis. | Q45200912 | ||
| Vascular risk factors and diabetic neuropathy | Q45240267 | ||
| Short-term hyperglycemia produces oxidative damage and apoptosis in neurons | Q45242262 | ||
| A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor | Q46417743 | ||
| A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. | Q46598018 | ||
| Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth | Q46603046 | ||
| LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium | Q46662739 | ||
| Oxidized LDL, a critical factor in atherogenesis | Q46777252 | ||
| Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stress. | Q46790318 | ||
| Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. | Q46809610 | ||
| Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein | Q46812171 | ||
| Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury. | Q46852186 | ||
| Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice | Q46918050 | ||
| Can drug screening lead to candidate therapies for testing in diabetic neuropathy? | Q46931580 | ||
| Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice | Q46943601 | ||
| Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice | Q46954782 | ||
| Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications | Q47726379 | ||
| Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. | Q49150383 | ||
| Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. | Q51480259 | ||
| PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. | Q51498703 | ||
| Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. | Q51498731 | ||
| Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. | Q51539892 | ||
| Neurons undergo apoptosis in animal and cell culture models of diabetes. | Q52536719 | ||
| Alzheimer's disease. A radical vascular connection. | Q53211163 | ||
| P433 | issue | 4 | |
| P921 | main subject | hyperlipidemia | Q1079120 |
| diabetic neuropathy | Q2046550 | ||
| P304 | page(s) | 257-267 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Journal of the Peripheral Nervous System | Q15764031 |
| P1476 | title | Hyperlipidemia: a new therapeutic target for diabetic neuropathy | |
| P478 | volume | 14 |
| Q35734707 | A controlled study of medial arterial calcification of legs: implications for diabetic polyneuropathy |
| Q37965408 | Advances in the laboratory evaluation of peripheral neuropathies |
| Q37126056 | An association analysis of lipid profile and diabetic cardiovascular autonomic neuropathy in a Chinese sample |
| Q36501212 | Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy. |
| Q37101622 | Association of comorbidities with increasing severity of peripheral neuropathy in diabetes mellitus |
| Q38006756 | Bioenergetics in diabetic neuropathy: what we need to know. |
| Q48324923 | Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study |
| Q93159371 | Chain length of saturated fatty acids regulates mitochondrial trafficking and function in sensory neurons |
| Q37572538 | Chewing the fat: genetic approaches to model dyslipidemia-induced diabetic neuropathy in mice |
| Q34805939 | Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes. |
| Q36879268 | Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes |
| Q35148853 | Detrimental impact of hyperlipidemia on the peripheral nervous system: A novel target of medical epidemiological and fundamental research study |
| Q41436213 | Diabetic Neuropathy Evaluated by a Novel Device: Sural Nerve Conduction Is Associated with Glycemic Control and Ankle-Brachial Pressure Index in Japanese Patients with Diabetes |
| Q91983712 | Diabetic neuropathy in children and adolescents with type 1 diabetes mellitus: Diagnosis, pathogenesis, and associated genetic markers |
| Q40670276 | Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin. |
| Q33878023 | Diabetic neuropathy part 1: overview and symmetric phenotypes |
| Q91762128 | Diabetic neuropathy research: from mouse models to targets for treatment |
| Q33678564 | Diabetic neuropathy: a cross-sectional study of the relationships among tests of neurophysiology |
| Q37930962 | Diabetic neuropathy: cellular mechanisms as therapeutic targets |
| Q34275990 | Diabetic neuropathy: clinical manifestations and current treatments |
| Q90779689 | Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention |
| Q36293649 | Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach? |
| Q37893102 | Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity |
| Q24601427 | Diagnosis and treatment of pain in small-fiber neuropathy |
| Q92813959 | Diet-Induced Rodent Models of Diabetic Peripheral Neuropathy, Retinopathy and Nephropathy |
| Q41790371 | Dyslipidemia as a contributory factor in etiopathogenesis of diabetic neuropathy |
| Q50114087 | Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons. |
| Q55019616 | Effect of combined dyslipidemia and hyperglycemia on diabetic peripheral neuropathy in alloxan-induced diabetic WBN/Kob rats. |
| Q37179497 | Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocin-induced diabetic C57Bl/6J mice. |
| Q35935501 | Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| Q83811795 | Effects of selenium on calcium signaling and apoptosis in rat dorsal root ganglion neurons induced by oxidative stress |
| Q37783301 | Emerging drugs for diabetic neuropathy. |
| Q47446449 | Enteric Glial Dysfunction Evoked by Apolipoprotein E Deficiency Contributes to Delayed Gastric Emptying. |
| Q36421364 | Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice |
| Q34242240 | Good nutritional control may prevent polyneuropathy after bariatric surgery |
| Q35223053 | Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons |
| Q37900148 | Immortalized adult rodent Schwann cells as in vitro models to study diabetic neuropathy |
| Q38006758 | Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy |
| Q35219367 | Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus |
| Q59138107 | Influence of Sex on Cognition and Peripheral Neurovascular Function in Diabetic Mice |
| Q33862382 | Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction. |
| Q38213041 | Mechanism of diabetic neuropathy: Where are we now and where to go? |
| Q39015184 | Mediators of diabetic neuropathy: is hyperglycemia the only culprit? |
| Q38085041 | Medical strategies to reduce amputation in patients with type 2 diabetes |
| Q37655239 | Mouse models of diabetic neuropathy |
| Q50098409 | Nebivolol, a β-blocker abrogates streptozotocin-induced behavioral, biochemical, and neurophysiological deficit by attenuating oxidative-nitrosative stress: a possible target for the prevention of diabetic neuropathy |
| Q37900473 | Neuropathy in prediabetes: does the clock start ticking early? |
| Q38607985 | Neuropathy-specific alterations in a Mexican population of diabetic patients. |
| Q44225729 | Neuroprotective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model |
| Q37154301 | Obesity and hyperlipidemia are risk factors for early diabetic neuropathy |
| Q35579658 | Phenotypic changes in diabetic neuropathy induced by a high-fat diet in diabetic C57BL/6 mice |
| Q37139753 | Physiology in Medicine: neuromuscular consequences of diabetic neuropathy |
| Q38468159 | Polyradiculopathy secondary to severe hypertriglyceridemia |
| Q38007899 | Prediabetic neuropathy: does it exist? |
| Q34128919 | Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: a cross-sectional study |
| Q36477770 | Protection of trigonelline on experimental diabetic peripheral neuropathy |
| Q34194723 | Sensory, psychological, and metabolic dysfunction in HIV-associated peripheral neuropathy: A cross-sectional deep profiling study |
| Q35599191 | Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: a novel model of type 1 diabetic hamsters induced by short-term high-fat / high-cholesterol diet and low-dose streptozotocin |
| Q89534387 | Statins and Neuropathic Pain: A Narrative Review |
| Q37140449 | Streptozotocin-induced diabetes partially attenuates the effects of a high-fat diet on liver and brain fatty acid composition in mice |
| Q35973863 | The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes. |
| Q28551366 | The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo |
| Q48713671 | The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes |
| Q35985421 | The emerging role of autophagy in the pathophysiology of diabetes mellitus |
| Q26772148 | The epidemiology and risk factors of chronic polyneuropathy |
| Q37436781 | The metabolic syndrome and neuropathy: therapeutic challenges and opportunities |
| Q37708207 | The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: a 6-year follow-up study |
| Q35063229 | Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. |
| Q48510140 | UPLC-Q-TOF/MS based metabolomic profiling of serum and urine of hyperlipidemic rats induced by high fat diet |
Search more.